Characterization and processing of prostate specific antigen (hK3) and human glandular kallikrein (hK2) secreted by LNCaP cells

Prostate Cancer and Prostatic Diseases

Volumn 2, Issue 2, 1999, Pages 91-97

  Vaisanen V ^a   Lovgren J ^b   Hellman, J ^a   Piironen, T ^a   Lilja, H ^b   Pettersson, K ^a  

^a UNIVERSITY OF TURKU   (Finland)

^b LUND UNIVERSITY   (Sweden)

Author keywords

Cancer; Kallikrein; LNCaP; proPSA; Prostate specific antigen

Indexed keywords

ALPHA 1 ANTICHYMOTRYPSIN; ALPHA 2 MACROGLOBULIN; ENZYME PRECURSOR; PROSTATE SPECIFIC ANTIGEN; SERINE PROTEINASE INHIBITOR; TISSUE KALLIKREIN;

ANTIGEN DETECTION; ANTIGEN PRESENTATION; ARTICLE; CANCER CELL; CELL GROWTH; CELL SECRETION; HUMAN; HUMAN CELL; ISOELECTRIC POINT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROTEIN ANALYSIS; SEMINAL PLASMA;

EID: 2442725962     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500289     Document Type: Article

References (30)

1. Clements JA. The human kallikrein gene family: a diversity of expression and function. Mol Cell Endocrin 1992; 99: C1-C6.
2. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol 1979; 17: 159-163.
3. Sensabaugh GE Isolation and characterization of a semen-specific protein from human seminal plasma: a potential new marker for semen identification. J Forensic Sci 1978; 23: 106-115.
4. Oesterling JE. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 1991; 145: 907-923.
5. Christensson A, Laurell CB, Lilja H. Enzymatic activity of prostate specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur. J. Biochem 1990; 194: 755-763.
6. Christensson A, Lilja H. Complex formation between protein C inhibitor and prostate-specific antigen in vitro and in human semen. Eur. J. Biochem 1994; 220: 45-53.
7. 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. Cancer Res 1991; 51: 222-226.
8. 1-antichymotrypsin. Clin Chem 1991; 37: 1618-1625.
9. 1-antichymotrypsin as an indicator of prostate cancer. J Urol 1993; 150: 100-105.
10. Rubin H. The biology and biochemistry of antichymotrypsin and its potential role as a therapeutic agent. Biol Chem Hoppe Seyler 1992; 373: 494-502.
11. Clements JA. The glandular kallikrein family of enzymes: tissue specific-expression and hormonal regulation. Endocrine Rev 1989; 10: 393-419.
12. Lövgren J et al. Activation of the zymogen form of prostate specific antigen (PSA) by human glandular kallikrein hK2: The zymogen form of prostate specific antigen (PSA) is activated by the human glandular killikrein hK2. Biochem Biophys Res Commun 1997; 238: 549-555.
13. Takayama TK, Fujikawa K, Davie EW. Characterization of the precursor of protate-specific antigen. Activation by trypsin and by human glandular kallikrein. J Biol Chem 1997; 272: 1582-21588.
14. Kumar A et al. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 1997; 57: 3111-3114.
15. Leinonen J, Zhang WM, Stenman U-H. Complex formation between PSA isoenzymes and protease inhibitors. J Urol 1996; 155: 1099-1103.
16. Wang MC et al. Prostate specific antigen of human cancer patients. In: Busch H and Yeoman LC (eds). Methods in Cancer Research: Tumor Markers Vol 19. Academic Press: New York, 1982, pp 179-197.
17. Huber PR et al. Serum free prostate specific antigen: isoenzymes in benign prostatic hyperplasia and cancer of the prostate. Prostate 1995; 27: 212-219.
18. Horoszewicz JS et al. LNCaP model of human prostatic carcinomia. Cancer Res 1983; 43: 1809-1818.
19. Veldscholte J et al. A mutation on the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens. Biochem Biophys Res Commun 1990; 173: 534-540.
20. Wilding G, Chen M, Gelman EP. Aberrant response in vitro of hormone-responsive prostate cancer cells to antiandrogens. Prostate 1989; 14: 103-115.
21. Kokontis, J, Kiyoshi I, Hiipakka RA, Liao S. Expression and function of normal and LNCaP androgen receptors in androgen intensitive human prostatic cancer cells. Receptor 1991; 1: 271-279.
22. 1-antichymotrypsin complex. Clin Chem 1995; 41: 1480-1488.
23. Lövgren J et al. Production of the recombinant PSA and hK2 and analysis of their immunologic cross-reactivity. Biochem Biophys Res Commun 1995; 213: 888-895.
24. Oesterling JE et al. Free, complexed and total serum prostate specific antigen: The establishment of appropriate reference ranges for their concentrations and ratios. J Urol 1995; 154: 1090-1095.
25. Piironen T et al. Immunofluorometric assay for sensitive and specific measurement of human prostatic glandular kallikrein (hK2) in serum. Clin Chem 1996; 42: 1034-1041.
26. Bairoch A, Apweiler R. The SWISS-PROT protein sequence data bank and its supplement TrEMBL. Nucleic Acids Res 1997; 25: 31-36.
27. Wu JT, Lyons BW, Liu GH, Wu LL. Production of milligram amounts of free prostate specific antigen (fPSA) from LNCaP cell culture: Difference between fPSA from LNCaP cell and seminal plasma. J Clin Lab Anal 1998; 12: 6-13.
28. Bélanger A et al. Molecular mass and carbohydrate structure of prostate specific antigen: Studies for establishment of an international PSA standard. Prostate 1995; 27: 187-197.
29. Mikolajczyk SD et al. A precursor form of PSA (pPSA) is a component of the free PSA in prostate cancer serum. Urology 1997; 50: 710-714.
30. Noldus J, Chen Z, Stamey TA. Isolation and characterization of free form of prostate specific antigen (f-PSA) in sera of men with prostate cancer. J Urol 1997; 158: 1606-1609.